Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

被引:13
|
作者
Zhang, Chao [1 ]
Denti, Paolo [1 ]
van der Walt, Jan-Stefan [1 ]
Ren, Yuan [1 ]
Smith, Peter [1 ]
Karlsson, Mats O. [2 ]
McIlleron, Helen [1 ]
机构
[1] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
基金
英国惠康基金;
关键词
lamivudine; population pharmacokinetics; NONMEM; CHILDREN; TUBERCULOSIS; RIFAMPICIN;
D O I
10.1097/FTD.0b013e31825c6067
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose reference lamivudine concentrations for evaluation of adherence to recent treatment doses. Methods: The steady state pharmacokinetics of lamivudine were evaluated in 68 young HIV-infected children receiving antiretroviral treatment twice daily. A population pharmacokinetic analysis was conducted using NONMEM 7. Results: A 2-compartment model with transit absorption best described lamivudine pharmacokinetics. After adjustment for maturation and body weight (using allometric scaling), the variability of clearance was small, hence simulations could accurately predict lamivudine concentrations. Higher lamivudine trough concentrations were detected before the morning dose, possibly owing to slower overnight clearance. Reference values for lamivudine concentrations that can be used to evaluate adherence to recent doses are proposed. Conclusions: Lamivudine concentration measurement can be used to assess recent treatment adherence.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条
  • [1] A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab
    Chang, Hsuan Ping
    Shakhnovich, Valentina
    Frymoyer, Adam
    Funk, Ryan Sol
    Becker, Mara L.
    Park, K. T.
    Shah, Dhaval K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 290 - 302
  • [2] Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin
    Zhang, Chao
    Denti, Paolo
    Decloedt, Eric H.
    Ren, Yuan
    Karlsson, Mats O.
    McIlleron, Helen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 741 - 751
  • [3] Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
    Kerbusch, T
    Huitema, ADR
    Ouwerkerk, J
    Keizer, HJ
    Mathôt, RAA
    Schellens, JHM
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (06) : 555 - 561
  • [4] Population pharmacokinetic model of levetiracetam in Korean neonates with seizures
    Jung, Yun Seob
    Lee, Soon Min
    Park, Min Soo
    Park, Kyungsoo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (05) : 217 - 223
  • [5] Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
    Vucicevic, Katarina
    Milijkovic, Branislava
    Velickovic, Ruzica
    Pokrajac, Milena
    Mrhar, Ales
    Grabnar, Iztok
    THERAPEUTIC DRUG MONITORING, 2007, 29 (06) : 781 - 788
  • [6] A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy
    Jung, Yun Seob
    Son, Mijeong
    Lee, Sang-Guk
    Chong, June-Won
    Kim, Soo-Jeong
    Jang, Ji Eun
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Kyungsoo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) : 849 - 862
  • [7] External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients
    Methaneethorn, Janthima
    Lohitnavy, Manupat
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (03) : 168 - 172
  • [8] Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis
    Abolhassani-Chimeh, Reihaneh
    Akkerman, Onno W.
    Saktiawati, Antonia M., I
    Punt, Nieko C.
    Bolhuis, Mathieu S.
    Subronto, Yanri W.
    Sumardi
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Alffenaar, Jan-Willem C.
    Sturkenboom, Marieke G. G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (07)
  • [9] Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model
    Kawuma, Aida N. N.
    Wasmann, Roeland E. E.
    Dooley, Kelly E. E.
    Maartens, Gary
    Denti, Paolo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (03) : 1216 - 1221
  • [10] A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing
    Llanos-Paez, C. C.
    Staatz, C. E.
    Lawson, R.
    Hennig, S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)